CLEVIPREX
Drug
Chiesi USA, Inc.
Total Payments
$3.8M
Transactions
28,908
Doctors
14,028
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $845,860 | 4,865 | 3,420 |
| 2023 | $520,327 | 4,884 | 3,443 |
| 2022 | $451,048 | 3,946 | 2,593 |
| 2021 | $332,355 | 5,401 | 3,291 |
| 2020 | $143,067 | 531 | 307 |
| 2019 | $518,851 | 3,806 | 2,127 |
| 2018 | $555,664 | 3,930 | 2,124 |
| 2017 | $385,782 | 1,545 | 916 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.4M | 525 | 36.4% |
| Food and Beverage | $709,730 | 25,361 | 18.9% |
| Honoraria | $643,121 | 341 | 17.1% |
| Consulting Fee | $336,417 | 48 | 9.0% |
| Travel and Lodging | $285,641 | 1,357 | 7.6% |
| Space rental or facility fees (teaching hospital only) | $207,869 | 162 | 5.5% |
| Grant | $179,900 | 5 | 4.8% |
| Gift | $11,829 | 252 | 0.3% |
| Education | $8,241 | 855 | 0.2% |
| Charitable Contribution | $3,900 | 2 | 0.1% |
Ad
Manufacturing Companies
- Chiesi USA, Inc. $3.5M
- CHIESI USA, INC. $257,477
Product Information
- Type Drug
- Total Payments $3.8M
- Total Doctors 14,028
- Transactions 28,908
About CLEVIPREX
CLEVIPREX is a drug associated with $3.8M in payments to 14,028 healthcare providers, recorded across 28,908 transactions in the CMS Open Payments database. The primary manufacturer is Chiesi USA, Inc..
Payment data is available from 2017 to 2024. In 2024, $845,860 was paid across 4,865 transactions to 3,420 doctors.
The most common payment nature for CLEVIPREX is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.4M, 36.4% of total).